Cylopenta[b]benzofuran derivatives and the utilization thereof

Details Cylopenta[b]benzofuran derivatives and the utilization thereof Cylopenta[b]benzofuran derivatives and the utilization thereof

2005-05-14

2011-10-04

Dentz, Bernard (Department: 1622)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S458000

Reexamination Certificate

active

08030347

ABSTRACT:
The present application relates to a novel cyclopenta[b]benzofuran derivatives, processes for their preparation and their use for the manufacture of medicaments, in particular for the prophylaxis and/or therapy of acute or chronic disorders characterized by elevated cellular stress, by local or systemic inflammatory processes or by hyperproliferation.

REFERENCES:
patent: 6518274 (2003-02-01), Gehling et al.
patent: 2003/0144334 (2003-07-01), Guarnieri et al.
patent: 0007579 (2000-02-01), None
patent: 0008007 (2000-02-01), None
Diedrichs, et al., A Highly Efficient Synthesis of Rocaglaols by a Novel α-Arylation of Ketones, Eur. J. Org. Chem., 9: 1731-1735 (2005).
Karin, M et al; “AP-1 function and regulation”; Current Opinion in Cell Biology; 1997; pp. 240-246.
Shaulian, E. et al; “AP-1 as a regulator of cell life and death”; Nature Cell Biology, vol. 4, May 2002, pp. E131-E136.
Holtmann, H., et al; “Induction of Interleukin-8 Synthesis Integrates Effects on Transcription and mRNA Degradation from at Least Three Different Cytokine- or Stress-Activated Signal Transduction Pathways”; Molecular and Cellular Biology, Oct. 1999, pp. 6742-6753.
Chang, Y, et al; “Lymphotoxin β Receptor Induces Interleukin 8 Gene Expression via NF -kB and AP-1 Activation”; Experimental Cell Research, 278, (2002); pp. 166-174.
Houston, et al; “Prediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices”; Drug Metabolism Reviews, 29 (4), 1997, pp. 891-922.
Silvestrini, et al; “In Vitro Cytotoxic Activity of Taxol® and Taxotere on Primary Cultures and Established Cell Lines of Human Ovarian Cancer”; Taxol ® and Taxotere in Ovarian Cancer Cells; Istituto Nazional per lo Studio e la Cura dei Tumori, Milan, Italy, published Aug. 2, 1993, AlphaMed Press; pp. 1066-5099.
Edelman, et al; “Promising new agents in the treatment of non-small cell lung cancer”; Cancer Chemother. Pharmacol. , 1996, 37, pp. 385-393.
Eijkenboom et al; “Effects of subdural haematoma on sensorimotor functioning and spatial learning in rats”; Neuro Pharmacology, 39, 2000, pp. 817-834.
Bissery et al; “Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience”; Anti-cancer Drugs 1995, vol. 6, pp. 339-368.

Affiliated with

Also associated with

Rating

Cylopenta[b]benzofuran derivatives and the utilization thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cylopenta[b]benzofuran derivatives and the utilization thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cylopenta[b]benzofuran derivatives and the utilization thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4300391